Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer : Nivea maker Beiersdorf names new CEO as Q1 sales rise

04/28/2021 | 04:41am EDT

BERLIN (Reuters) - Nivea maker Beiersdorf on Wednesday named board member Vincent Warnery as its new CEO to take over from May 1, as it confirmed a rise in first-quarter sales driven by strong demand for adhesives and its dermatological brands.

Beiersdorf said Stefan de Loecker will step down after a little more than two years in the job. His mandate will end on June 30.

Under de Loecker's leadership, Beiersdorf invested more in its consumer business to counter a drop in sales growth and bought U.S. sun care brand Coppertone from Bayer for $550 million to strengthen its position in North America.

The Hamburg-based firm, which pre-released first-quarter results earlier this month, confirmed group sales rising 6.3% to a pre-crisis level of 1.9 billion euros ($2.29 billion) in the three months of the year. It said online sales jumped by more than 70% in the quarter.

It reaffirmed its full-year 2021 EBIT (earnings before interest and tax) margin forecast would be level with last year's as the pandemic continues to hit sales of sun and lip care products.

Shares in the company were up 0.9% at 0743 GMT.

($1 = 0.8284 euros)

(Reporting by Riham Alkousaa; Editing by Maria Sheahan and Barbara Lewis)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -1.06% 52.19 Delayed Quote.8.38%
BEIERSDORF AG -0.82% 102.4 Delayed Quote.8.43%
All news about BAYER AG
06/21Bayer Files for U.S., EU Approval of Aliqopa/Rituximab Combo
06/21BAYER  : Seeks Approval For Cancer Treatment Combinations In US, EU
06/21Germany's BaFin looking into possible insider trading of CureVac shares
06/21BAYER  : submits regulatory applications for oncology treatment combination of c..
06/21BAYER AG  : Deutsche Bank keeps its Buy rating
06/18PRESS RELEASE  : BioNTech Announces First Patient Dosed in Phase 2 Clinical Tria..
06/18CureVac Could Allow Manufacturing Partners To Produce Rival Vaccines
06/17SECTOR UPDATE : Health Care Stocks Add to Afternoon Gains
06/17CureVac may let contractors make rival vaccines if own shot fails -CEO
06/17SECTOR UPDATE : Health Care Stocks Maintaining Modest Thursday Advance
More news
Sales 2021 41 349 M 49 246 M 49 246 M
Net income 2021 3 593 M 4 280 M 4 280 M
Net Debt 2021 38 658 M 46 042 M 46 042 M
P/E ratio 2021 15,3x
Yield 2021 3,88%
Capitalization 51 273 M 61 083 M 61 066 M
EV / Sales 2021 2,17x
EV / Sales 2022 2,05x
Nbr of Employees 99 329
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 64,63 €
Last Close Price 52,19 €
Spread / Highest target 62,9%
Spread / Average Target 23,8%
Spread / Lowest Target -50,3%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG8.38%61 083
JOHNSON & JOHNSON4.10%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.7.09%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.7.07%199 795